The post Strategy Buys $109M in Bitcoin as Corporate BTC Treasuries Expand in 2025 appeared on BitcoinEthereumNews.com. Strategy announced its latest Bitcoin purchaseThe post Strategy Buys $109M in Bitcoin as Corporate BTC Treasuries Expand in 2025 appeared on BitcoinEthereumNews.com. Strategy announced its latest Bitcoin purchase

Strategy Buys $109M in Bitcoin as Corporate BTC Treasuries Expand in 2025

For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

Strategy announced its latest Bitcoin purchase of 2025, adding 1,229 BTC after a year of accelerated accumulation that saw the company disclose more acquisitions than in the previous two years combined.

According to a Form 8-K filed on Monday, the coins were acquired Dec. 22-28 for an aggregate purchase price of $108.8 million, funded through at-the-market stock sales.

The purchase brings Strategy’s total Bitcoin holdings to 672,497 BTC (BTC) at an average purchase price of $74,997 per coin, according to the filing.

It also ranks among the company’s smaller acquisitions this year. According to data from SaylorTracker.com, Strategy’s largest Bitcoin purchase in 2025 came on March 31, when it acquired about 22,049 BTC for roughly $1.92 billion, followed by buys of about 21,021 BTC for $2.46 billion on July 29 and 20,356 BTC for $1.99 billion on Feb. 24.

SaylorTracker data also shows Strategy disclosed Bitcoin purchases in 41 separate weeks in 2025, up from 18 purchases in 2024 and eight in 2023. The company ended 2024 holding 447,470 Bitcoin, based on its regulatory filings.

Source: Strategy

Led by co-founder and executive chairman Michael Saylor, Strategy began accumulating Bitcoin in 2020 and remains the largest corporate holder by a wide margin. MARA Holdings ranks second among public Bitcoin treasury companies, with 53,250 BTC on its balance sheet, data from BitcoinTreasuries.NET shows.

Strategy has been funding its Bitcoin purchases through at-the-market stock offerings, tapping both common and preferred share programs to raise capital. From Dec. 22 to Dec. 28, the company sold 663,450 shares of its Class A common stock for $108.8 million in net proceeds.

The latest buy brings Strategy’s year-to-date BTC yield to 23.2%, a metric the company uses to measure how much its Bitcoin holdings have grown relative to shares outstanding.

Related: Bitcoin market fundamentals ‘couldn’t be better,’ says Strategy CEO

Public companies holding Bitcoin expand in 2025

Publicly traded companies now hold more than 1.08 million Bitcoin across 192 public companies, the majority of which are based in the United States, followed by Canada, the United Kingdom and Japan.

Corporate holders also account for the largest share of Bitcoin-holding entities by count, outpacing governments, private companies and DeFi protocols. 

A Bitcoin treasury company is a company that uses Bitcoin as a core balance-sheet asset, raising capital through equity or debt to acquire and hold BTC.

Entities holding BTC by country. Source: BitcoinTreasuries.NET

Following Strategy’s steps, Twenty One Capital launched its Bitcoin treasury strategy in April and now holds more than 43,500 BTC. The company is backed by Cantor Fitzgerald, Tether, SoftBank and Bitfinex, and added roughly 5,800 BTC from Tether in July.

Several other companies either went public or announced Bitcoin treasury strategies in 2025, including Bullish, which went public in August and holds roughly 24,300 BTC, followed by Bitcoin Standard Treasury Company with about 30,021 BTC, Trump Media & Technology Group with about 11,542 BTC, and GD Culture Group with about 7,500 BTC.

Top 20 Bitcoin treasury companies. Source: BitcoinTreasuries.NET

Magazine: Big questions: Would Bitcoin survive a 10-year power outage?

Source: https://cointelegraph.com/news/strategy-bitcoin-purchase-active-2025-accumulation?utm_source=rss_feed&utm_medium=feed&utm_campaign=rss_partner_inbound

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09